ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Shenzhen Salubris Pharmaceuticals Co., Ltd. clinical trials

Part of 信立泰药业有限公司 (Hong Kong), which holds 56.99% as of 2025-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 49 studies whose lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. or one of 2 companies grouped under it. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Shenzhen Salubris Pharmaceuticals with Amgen and Jiangsu HengRui Medicine →

Pipeline: 20 programs

Each counted once: 20 with a study Shenzhen Salubris Pharmaceuticals Co., Ltd. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 6 with the most live studies.

Program
SAL-0951Phase 3 · 1 live · Anemia☆ Track
SAL0120Phase 3 · 1 live · Hypertension☆ Track
SAL056Phase 3 · 1 live · Osteoporosis☆ Track
SAL003Phase 3 · 0 live · Hypercholesterolemia☆ Track
SAL067Phase 3 · 0 live · Diabetes Mellitus, Type 2☆ Track

1 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Shenzhen Salubris Pharmaceuticals Co., Ltd.’s own registered studies; Shenzhen Salubris Pharmaceuticals Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Shenzhen Salubris Pharmaceuticals Co., Ltd.’s studies test, most open studies first — 11 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 1 more

Coming up

8 of Shenzhen Salubris Pharmaceuticals Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. F
  5. 1M
  6. 1A
  7. M
  8. 1J
  9. 1J
  10. A
  11. S
  12. 2O
  13. 1N

Add all 8 to your calendar (.ics) → With an account.

All 49 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1939%Recruiting 9 · Not yet recruiting 9 · Enrolling by invitation 1
  • Under way, not recruiting612%
  • Completed1939%
  • Stopped early24%
  • Status unknown or other36%

Phase

  • Phase 116
  • Phase 216
  • Phase 314
  • Phase 42

Where

  • China43
  • United States4
  • Belgium2
  • Spain2
  • Canada1
  • Puerto Rico1

Over the years

  1. 16
  2. 17
  3. 18
  4. 19
  5. 20
  6. 21
  7. 22
  8. 23
  9. 24
  10. 1025
  11. 1026

By the year each study started; 1 started before 2016. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shenzhen Salubris Pharmaceuticals Co., Ltd.

  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    42 studies
  • Salubris Biotherapeutics Inc
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • ShenZhen KYD Biomedical Technology Co., Ltd.
    Acquired — became part of Shenzhen Salubris Pharmaceuticals Co., Ltd., Nov 30, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Studies

Recruiting first, then most recently updated. Showing 49 of 49.